The protocol calls for study participants to be randomized to get either the TCAD therapy comprised of amantadine and ribavirin with oseltamivir or oseltamivir monotherapy for 10 times. The follow-up period will end up being six months pursuing treatment and an Independent Data Monitoring Committee will monitor the basic safety of participants throughout the duration of the analysis. There is a clear dependence on alternative antiviral strategies to treat influenza, especially for immune-compromised individuals at risk for development of drug resistance and severe medical outcomes, stated Menno de Jong, M.D., Ph.D., professor in Clinical Virology at the Department of Medical Microbiology, Academic Medical Center of the University of Amsterdam, and Seat of the Process Steering Committee for this Phase 2 trial.All they need to do is definitely search Google Scholar for just one published scientific content proving the basic safety and performance of any H1N1 swine flu vaccine through two randomized, double-blind, placebo-controlled studies based on the criteria described right here. It’s simple, actually. If such scientific proof exists, it will require less than one hour to find it. With all these doctors, journalists and FDA decision makers discussing the amazing technology behind the H1N1 vaccines, you would think that there should be at least one of these who want to earn $10,000 in a single hour while proving the basic safety and efficacy of the vaccines.